Pharming reduces debt in share issuance
This article was originally published in Scrip
Executive Summary
Pharming, the Dutch biotech company, has converted private bonds into 7.8 million new shares to improve its capital structure amid the launch of its lead product Rhucin (recombinant human C1 inhibitor).